Anyara naptumomab estafenatox: Additional Phase II/III data

In a subgroup analysis of the 25% of patients with low or normal levels of baseline IL-6 and expected anti-superantigen antibody levels, Anyara plus IFN alpha led to a median OS of 63.3 months vs. 31.1 months for IFN alpha alone (p=0.02) and a median PFS of 13.7 months vs. 5.8 months for IFN alpha alone (p=0.016). In the subgroup, Anyara plus IFN alpha led to an ORR of 28% vs. 16% for IFN alpha alone. Active Biotech said the data warrant further studies of Anyara in sequence or in combination with tyrosine kinase inhibitors (TKIs) in the subgroup, but could not be reached for details. Data will be presented at the American Society of Clinical Oncology meeting in Chicago in June. ...